In Brief: Abbott
This article was originally published in The Gray Sheet
Executive Summary
Abbott: Receives FDA go-ahead to market its automated assay for detection of hepatitis B surface antigen. The test, which employs microparticle enzyme immunoassay technology, is designed for use on Abbott's IMx immunoassay instrument system. Havab and Havab-M for the detection of hepatitis A antibodies and Core-M for the detection of IgM antibodies to hepatitis B core already are available on the IMx system...